The emerging role of myeloid-derived suppressor cells in lung diseases

European Respiratory Journal

Volumn 47, Issue 3, 2016, Pages 967-977

  Kolahian, Saeed ^a,b   Öz, Hasan Halit ^a   Zhou, Benyuan ^a   Griessinger, Christoph M ^a   Rieber, Nikolaus ^a,c   Hartl, Dominik ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TABRIZ   (Iran)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE;

ARTICLE; ASTHMA; CELL EXPANSION; CELL FUNCTION; CELL PLASTICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; HUMAN; IMMUNOREGULATION; LUNG CANCER; LUNG DISEASE; LUNG INFECTION; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUBERCULOSIS; IMMUNOLOGY; LUNG TUMOR; MYELOID-DERIVED SUPPRESSOR CELL; T LYMPHOCYTE;

ASTHMA; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MYELOID-DERIVED SUPPRESSOR CELLS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; T-LYMPHOCYTES; TUBERCULOSIS;

EID: 84959898840     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01572-2015     Document Type: Article

References (151)

1. Strober S, Okada S, Oseroff A. Role of natural suppressor cells in allograft tolerance. Fed Proc 1984; 43: 263-265.
2. Buessow SC, Paul RD, Lopez DM. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. J Natl Cancer Inst 1984; 73: 249-255.
3. Young MR, Endicott RA, Duffie GP, et al. Suppressor alveolar macrophages in mice bearing metastatic Lewis lung carcinoma tumors. J Leukoc Biol 1987; 42: 682-688.
4. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739-752.
5. Saleem SJ, Conrad DH. Hematopoietic cytokine-induced transcriptional regulation and notch signaling as modulators of MDSC expansion. Int Immunopharmacol 2011; 11: 808-815.
6. Gabrilovich DI. Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate? J Leukoc Biol 2014; 96: 671-674.
7. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Natur Rev Immunol 2009; 9: 162-174.
8. Cripps JG, Gorham JD. MDSC in autoimmunity. Int Immunopharmacol 2011; 11: 789-793.
9. Dumitru CA, Moses K, Trellakis S, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012; 61: 1155-1167.
10. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor bearing mice. J Immunol 2008; 181: 5791-5802.
11. Youn JI, Collazo M, Shalova IN, et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012; 91: 167-181.
12. Gallina G, Dolcetti L, SeraWni P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8 + T cells. J Clin Invest 2006; 116: 2777-2790.
13. Rößner S, Voigtländer C, Wiethe C, et al. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 2005; 35: 3533-3544.
14. Mazzoni A, Bronte V, Visintin A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168: 689-695.
15. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-228.
16. Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-4513.
17. Serafini P, Carbley R, Noonan KA, et al. High-Dose GM-CSF-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-6343.
18. Young MR, Wright MA, Coogan M, et al. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol Immunother 1992; 35: 14-18.
19. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996; 156: 73-78.
20. Alleva DG, Walker TM, Elgert KD. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages. J Leukoc Biol 1995; 57: 919-928.
21. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b +myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
22. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14: 408-419.
23. Foell D, Wittkowski H, Vogl T, et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
24. Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181: 4666-4675.
25. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 2273-2284.
26. Li L, Zhang J, Diao W, et al. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol 2014; 192: 1034-1043.
27. Rieber N, Brand A, Hector A, et al. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol 2013; 190: 1276-1284.
28. Rieber N, Singh A, Öz H, et al. Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor cells. Cell Host Microbe 2015; 17: 507-514.
29. Youn JI, Kumar V, Collazo M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013; 14: 211-220.
30. Corzo CA, Condamine T, Lu L, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-2453.
31. Condamine T, Kumar V, Ramachandran IR, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest 2014; 124: 2626-2639.
32. Greifenberg V, Ribechini E, Rößner S, et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development. Eur J Immunol 2009; 39: 2865-2876.
33. Rieber N, Gille C, Köstlin N, et al. Neutrophilic myeloid derived suppressor cells in cord blood modulate innate and adaptive immune responses. Clin Exp Immunol 2013; 174: 45-52.
34. Dietlin TA, Hofman FM, Lund BT, et al. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol 2007; 81: 1205-1212.
35. Szuster-Ciesielska A, Hryciuk-Umer E, Stepulak A, et al. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol 2004; 43: 252-258.
36. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006; 5: 14.
37. Mantovani G, Macciò A, Madeddu C, et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 2003; 81: 664-673.
38. Agostinelli E, Seiler N. Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids 2006; 31: 341-355.
39. Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-999.
40. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001; 11: 173-186.
41. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5: 641-654.
42. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222: 180-191.
43. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202: 931-939.
44. Rodriguez PC, Zea AH, Culotta KS, et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 2002; 277: 21123-21129.
45. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109: 1568-1573.
46. Bingisser R, Tilbrook P, Holt P, et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998; 160: 5729-5734.
47. Harari O, Liao JK. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm 2004; 10: 893-898.
48. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188: 97-113.
49. Vickers SM, MacMillan-Crow LA, Green M, et al. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg 1999; 134: 245-251.
50. Cobbs CS, Whisenhunt TR, Wesemann DR, et al. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 2003; 63: 8670-8673.
51. Bentz BG, Haines GK III, Radosevich JA. Increased protein nitrosylation in head and neck squamous cell carcinogenesis. Head Neck 2000; 22: 64-70.
52. Dairou J, Dupret JM, Rodrigues-Lima F. Impairment of the activity of the xenobiotic-metabolizing enzymes arylamine N-acetyltransferases 1 and 2 (NAT1/NAT2) by peroxynitrite in mouse skeletal muscle cells. FEBS Lett 2005; 579: 4719-4723.
53. Ekmekcioglu S, Ellerhorst J, Smid CM, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6: 4768-4775.
54. Kinnula VL, Torkkeli T, Kristo P, et al. Ultrastructural and chromosomal studies on manganese superoxide dismutase in malignant mesothelioma. Am J Respir Cell Mol Biol 2004; 31: 147-153.
55. Yang R, Cai Z, Zhang Y, et al. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1 +CD11b+ myeloid cells. Cancer Res 2006; 66: 6807-6815.
56. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131.
57. Zhu B, Bando Y, Xiao S, et al. CD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis. J Immunol 2007; 179: 5228-5237.
58. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood 2008; 111: 4233-4244.
59. Sinha P, Clements VK, Bunt SK, et al. Crosstalk between myeloid derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-983.
60. Shime H, Kojima A, Maruyama A, et al. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J Innate Immun 2014; 6: 293-305.
61. Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138: 105-115.
62. Ostrand-Rosenberg S, Sinha P, Beury DW, et al. Cross-talk between myeloid derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor induced immune suppression. Semin Cancer Biol 2012; 22: 275-281.
63. Murai M, Turovskaya O, Kim G, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009; 10: 1178-1184.
64. Ma Y, Shurin GV, Gutkin DW, et al. Tumor associated regulatory dendritic cells. Semin Cancer Biol 2012; 22: 298-306.
65. Shurin MR, Naiditch H, Zhong H, et al. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 2011; 11: 988-992.
66. Shurin GV, Ouellette CE, Shurin MR. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother 2012; 61: 223-230.
67. low regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009; 182: 6207-6216.
68. Niedermeier M, Reich B, Rodriguez Gomez M, et al. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA 2009; 106: 17892-17897.
69. Zoso A, Mazza EM, Bicciato S, et al. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol 2014; 44: 3307-3319.
70. Shi Y, Ou L, Han S, et al. Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. Oncogenesis 2014; 3: e129.
71. Hong KM, Belperio JA, Keane MP, et al. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007; 282: 22910-22920.
72. Mehner C, Radisky DC. Triggering the landslide: the tumor-promotional effects of myofibroblasts. Exp Cell Res 2013; 319: 1657-1662.
73. van Deventer HW, Palmieri DA, Wu QP, et al. Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2. J Immunol 2013; 190: 4861-4867.
74. Srivastava MK, Sinha P, Clements VK, et al. Myeloid derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70: 68-77.
75. Arora M, Poe SL, Oriss TB, et al. TLR4/MyD88-induced CD11b+Gr-1intF4/80+ non-migratory myeloid cells suppress Th2 effect or function in the lung. Mucosal Immunol 2010; 3: 578-593.
76. Zhang YL, Luan B, Wang XF, et al. Peripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development. PLoS One 2013; 8: e63775.
77. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol 2009; 625: 41-54.
78. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828-835.
79. Feng PH, Lee KY, Chang YL, et al. CD14(+)S100A9(+) monocytic myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med 2012; 186: 1025-1036.
80. -/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136: 35-45.
81. Bronte V, Serafini P, De Santo C, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170: 270-278.
82. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32: 19-25.
83. Bogdan C. Regulation of lymphocytes by nitric oxide. Methods Mol Biol 2011; 677: 375-393.
84. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048.
85. Liu Y, Van Ginderachter JA, Brys L, et al. Nitric oxide independent CTL suppression during tumor progression: association with arginase producing (M2) myeloid cells. J Immunol 2003; 170: 5064-5074.
86. Jackaman C, Nelson DJ. Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts? Exp Gerontol 2014; 54: 53-57.
87. Sawanobori Y, Ueha S, Kurachi M, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008; 111: 5457-5466.
88. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
89. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
90. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 8: 98-101.
91. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
92. Sceneay J, Chow MT, Chen A, et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012; 72: 3906-3911.
93. Srivastava MK, Sharma S, Zhu L, et al. Abstract 17. Tumor Snail knockdown reduces tumor burden and metastases by inducing antitumor immune responses in lung cancer. Cancer Res 2011; 71: Suppl. 18, A17.
94. Sawant A, Schafer CC, Jin TH, et al. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res 2013; 73: 6609-6620.
95. Srivastava MK, Zhu L, Harris-White M, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7: e40677.
96. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011; 71: 5101-5110.
97. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
98. Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-1430.
99. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, et al. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35: 107-115.
100. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307.
101. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63: 4441-4449.
102. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721.
103. Ko HJ, Kim YJ, Kim YS, et al. A combination of chemoimmunotherapies can efficiently break selftolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007; 67: 7477-7486.
104. Melani C, Sangaletti S, Barazzetta FM, et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67: 11438-11446.
105. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-2522.
106. Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506-2513.
107. Yanagawa J, Walser TC, Zhu LX, et al. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res 2009; 15: 6820-6829.
108. Talmadge JE, Hood KC, Zobel LC, et al. Chemoprevention bycyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol 2007; 7: 140-151.
109. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691-2702.
110. Qin H, Lerman B, Sakamaki I, et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 2014; 20: 676-681.
111. Arora M, Poe SL, Ray A, et al. LPS-induced CD11b+Gr1(int)F4/80+ regulatory myeloid cells suppress allergen-induced airway inflammation. Int Immunopharmacol 2011; 11: 827-832.
112. Song C, Yuan Y, Wang XM, et al. Passive transfer of tumour-derived MDSCs inhibits asthma-related airway inflammation. Scand J Immunol 2014; 79: 98-104.
113. Shi M, Shi G, Tang J, et al. Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice. J Allergy Clin Immunol 2014; 134: 1163-1174.
114. 2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498-5505.
115. Morales JK, Saleem SJ, Martin RK, et al. Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses. J Leukoc Biol 2014; 95: 643-650.
116. Deshane J, Zmijewski JW, Luther R, et al. Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung inflammation and airway hyperresponsiveness. Mucosal Immunol 2011; 4: 503-518.
117. Deshane JS, Redden DT, Zeng M, et al. Subsets of airway myeloid-derived regulatory cells distinguish mild asthma from chronic obstructive pulmonary disease. J Allergy ClinImmunol 2015; 135: 413-424.
118. Scrimini S, Pons J, Agustí A, et al. Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. Respir Med 2013; 107: 1895-1903.
119. Ortiz ML, Lu L, Ramachandran I, et al. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res 2014; 2: 50-58.
120. Kalathil SG, Lugade AA, Pradhan V, et al. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 190: 40-50.
121. Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1: PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008; 181: 116-125.
122. Lazar-Molnar E, Chen B, Sweeney KA Jr, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci USA 2010; 107: 13402-13407.
123. Wang X, Cao Z, Jiang J, et al. Elevated expression of Tim-3 on CD8 T cells correlates with disease severity of pulmonary tuberculosis. J Infect 2011; 62: 292-300.
124. Qiu Y, Chen J, Liao H, et al. Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS Pathog 2012; 8: e1002984.
125. Jiang J, Wang X, Wang X, et al. Reduced CD27 expression on antigen-specific CD4+ T cells correlates with persistent active tuberculosis. J Clin Immunol 2010; 30: 566-573.
126. du Plessis N, Loebenberg L, Kriel M, et al. Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 2013; 188: 724-732.
127. Yang B, Wang X, Jiang J, et al. Identification of CD244-expressing myeloid-derived suppressor cells in patients with active tuberculosis. Immunol Lett 2014; 158: 66-72.
128. Knaul JK, Jörg S, Oberbeck-Mueller D, et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med 2014; 190: 1053-1066.
129. Stenmark KR, Frid MG, Yeager ME. Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Eur Respir J 2010; 36: 1232-1235.
130. Perros F, Dorfmüller P, Souza R, et al. Dendritic cell recruitmentvin lesions of human and experimental pulmonary hypertension. Eur Respir J 2007; 29: 462-468.
131. Ulrich S, Nicolls MR, Taraseviciene L, et al. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 2008; 75: 272-280.
132. Austin ED, Rock MT, Mosse CA, et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med 2010; 104: 454-462.
133. Yeager ME, Nguyen CM, Belchenko DD, et al. Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest 2012; 141: 944-952.
134. Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000; 120: 518-525.
135. Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010; 120: 3242-3254.
136. Hartl D, Griese M, Kappler M, et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117: 204-211.
137. Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest 2008; 118: 413-420.
138. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 2010; 10: 427-439.
139. Poe SL, Arora M, Oriss TB, et al. STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. Mucosal Immunol 2013; 6: 189-199.
140. De Santo C, Salio M, Masri SH, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 2008; 118: 4036-4048.
141. Zhang C, Lei GS, Shao S, et al. Accumulation of myeloid-derived suppressor cells in the lungs during Pneumocystis pneumonia. Infect Immun 2012; 80: 3634-3641.
142. Lei GS, Zhang C, Lee CH. Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia. Infect Immun 2015; 83: 572-582.
143. Zhang DH, Cohn L, Ray P, et al. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 1997; 272: 21597-21603.
144. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4T cells. Cell 1997; 89: 587-596.
145. Zhu J, Cote-Sierra J, Guo L, et al. Stat5 activation plays a critical role in Th2 differentiation. Immunity 2003; 19: 739-748.
146. Hu H, Huston G, Duso D, et al. CD4(+) T cell effectors can become memory cells with high efficiency and without further division. Nat Immunol 2001; 2: 705-710.
147. De Wilde V, Van Rompaey N, Hill M, et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am J Transplant 2009; 9: 2034-2047.
148. Nefedova Y, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004; 172: 464-474.
149. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010; 120: 457-471.
150. Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68: 5439-5449.
151. Varga G, Ehrchen J, Tsianakas A, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 2008; 84: 644-650.